<DOC>
	<DOCNO>NCT02899455</DOCNO>
	<brief_summary>A phase 3 study evaluate efficacy safety Co-administered HGP0904 , HGP0608 HGP0816 Patients Hypertension Dyslipidemia</brief_summary>
	<brief_title>Clinical Efficacy Safety Evaluation Co-administered HGP0904 , HGP0608 HGP0816 Patients With Hypertension Dyslipidemia</brief_title>
	<detailed_description>This study design multi-center , double-blinded , randomize , phase 3 clinical trial evaluate efficacy safety Co-administered HGP0904 , HGP0608 HGP0816 Patients Hypertension Dyslipidemia</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>1 . 19 ≤ age ≤ 75 2. Visit 1 1 ) BP : sitDBP ≥ 90mmHg 2 ) Cholesterol : LDLC ≤ 250mg/dL , TG &lt; 400mg/dL 3. Visit 2 : TLC ( 4weeks ) 1 ) BP : 80 mmHg ≤ sitDBP &lt; 110mmHg 2 ) Cholesterol : follow risk category ( Cardiovascular Risk category ) A : CHD risk factor 0 1 , 160mg/dL ≤ LDLC ≤ 250mg/dL B① : CHD risk factor≥2 10 year risk &lt; 10 % , 160mg/dL ≤ LDLC ≤ 250mg/dL B② : CHD risk factor≥2 10 year risk =1020 % , 130mg/dL ≤ LDLC ≤ 250mg/dL C : CHD/CHD risk equivalents* 10 year risk &gt; 20 ,100mg/dL ≤ LDLC ≤ 250mg/dL 3 ) TG &lt; 400mg/dL 4 . Patients understood content purpose trial sign informed consent form 1 . At Visit 1 , BP difference SBP ≥20mmHg DBP ≥10mmHg 2 . Tolerance Hypersensitivity Angiotensin II receptor blocker HMGCoA . reductase inhibitor , Calcium channel blocker ( dihydropyridine ) Multidrug allergy 3 . Fibromyalgia , myopathy , rhabdomyolysis acute myopathy medical history adverse effect statin 4 . CPK normal range ≥ 3times 5 . Uncontrolled primary hypothyroidism ( TSH normal range ≥ 2 time ) 6 . Renal disease suspect renal disease ( Scr ≥ 2mg/dL , AST ALT≥2 time ) 7 . Active gout hyperuricemia ( Visit 1 , uric acid &gt; 9mg/dL ) 8 . IDDM uncontrolled diabetes mellitus ( HbA1c &gt; 9 % ) 9. ventricular arrhythmia 10. medical history severe cerebrovascular disease within 6 month ( cerebral infarction , cerebral hemorrhage ) , hypertension encephalopathy , transient cerebral ischemic attack ( TIA ) severe heart disease ( heart failure NYHA class IIIIV ) , valvular disease heart myocardial infarction unstable angina angioplasty coronary artery bypass graft ( CABG ) surgery within 6months</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>